BPC-157

Shop high-purity BPC 157 5mg vials at Eternal Peptides, the industry leader in verified quality and experimental consistency. Our BPC-157 is synthesized to a standard of ≥99% purity, with every batch supported by independent third-party COAs (Janoshik) to ensure reliable laboratory results. We provide full traceability for individual and bulk purchases, backed by 24/7 US-based support. Order today for fast, secure shipping and free Priority delivery on all orders over $200.

What is BPC 157?

BPC157 (body protection compound-157) is a synthetic pentadecapeptide modeled after a partial sequence of a gastric protein known as BPC. It was first characterized as a stable peptide fragment present in gastric juice.

Preclinical research-largely in vitro and in rodent injury models-indicates that BPC-157 may influence multiple repair-related processes, including angiogenesis, extracellular-matrix remodeling, and cytoprotection in tendon, muscle, bone, and gastrointestinal tissues. These findings, however, are not validated in controlled human trials, and the current evidence base remains almost entirely preclinical.

How BPC157 Works (Mechanism of Action)

As per studies and existing in the field, BPC-157 exhibits pleiotropic activity, interacting with multiple regulatory pathways rather than targeting a single receptor. These mechanistic insights come predominantly from cellular assays and animal studies.

Angiogenesis and VEGF/VEGFR2

Studies indicate that BPC-157 can modulate vascular endothelial growth factor (VEGF) expression and VEGFR2 activity, stimulating Akt–eNOS pathways linked to endothelial stabilization, angiogenesis, and tissue revascularization[1]. 

This means BPC-157 may help blood vessels grow and repair themselves more efficiently. By promoting these vascular processes, tissues that have been damaged or are healing-such as muscles, tendons, or gut lining-may receive improved blood flow, oxygen, and nutrients. This enhanced microcirculation can support faster recovery and maintain the health of endothelial cells that line the blood vessels, which is a critical component of overall tissue repair and regeneration.

Nitric-oxide modulation and cytoprotection

Studies suggest that BPC-157 can counteract harmful nitric oxide (NO) overproduction while supporting normal physiological NO signalling, contributing to cytoprotection in severe injury models[2].

That means BPC-157 may help maintain a healthy balance of nitric oxide in the body, which is important for blood flow, immune response, and tissue function. However, excessive NO levels can damage cells and tissues, so regulating NO may help protect cells from injury, reduce tissue stress, and support the healing of damaged muscles, tendons, or organs.

This balanced effect is especially important during severe injury, where uncontrolled NO could otherwise worsen tissue damage.

Anti-inflammatory signalling and ECM interactions

According to preclinical models, BPC-157 may affect inflammation and help remodel the extracellular matrix, which is the scaffold supporting tissues. By interacting with proteins like FAK and paxillin, it may speed up cell migration and tissue repair, helping wounds or damaged tissues recover more efficiently[3].

Gastrointestinal mucosal protection

BPC-157 has been shown in animal studies to help heal the lining of the stomach and intestines. It can reduce damage from ulcer-causing agents and promote mucosal repair, supporting the integrity of the gut barrier[4]. This effect may help protect digestive tissues and maintain normal gastrointestinal function.

CNS-related findings

Some preclinical studies suggest BPC-157 may have neuroprotective effects. It appears to reduce neuroinflammation and support the health of blood vessels in the brain, which may help maintain tissue function after injury or stress[5]. These findings are mostly from animal models, so clinical relevance in humans is not yet established.

BPC-157 Research Value

BPC-157 shows a variety of research benefits, especially in studying tissue regeneration, inflammatory response, and microvascular stability.

Multi-pathway activity relevant to tissue repair

Preclinical work shows consistent effects across models of wound healing, tendon or ligament injury, muscle damage, and GI irritation. Researchers value it because it seems to influence several systems at once – inflammation, angiogenesis, nitric oxide signalling, and ECM remodeling – giving a broader view of how these pathways interact during tissue recovery.

Angiogenesis and vascular stability

Rodent studies suggest BPC-157 may support capillary repair and microvascular stability[7]. This makes it useful for studying how blood flow changes affect healing, especially in ischemic or mechanically stressed tissues.

Mucosal protection and epithelial integrity

Early research focused on the GI tract, where BPC-157 repeatedly showed protective effects against ulceration and toxin-induced damage[7]. As a result, it’s often used to explore how the gut lining maintains barrier function under stress.

Systemic coordination of healing

Some studies highlight tissue improvements distant from the injury site, which has led researchers to use BPC-157 as a model for investigating whole-body healing responses rather than isolated, single-tissue effects.

BPC-157 Peptide Characteristics

Molecular Formula: C62H98N16O22

Batch: EP-250407-BPC05

Handling & Storage Guidelines

• Store lyophilized powder at –4°F (–20°C) protected from moisture and light.
• Reconstitute using bacteriostatic water or approved solvents.
• Aliquot after reconstitution and avoid repeated freeze-thaw cycles
• Use fresh working dilutions where possible; short-term storage at –39.2°F (4°C) may be acceptable depending on experimental protocols.

Storage Guidelines (500 mcg tablets)

• Store sealed at room temperature or 35.8°F – 46.4°F (2–8°C).
• Protect from humidity.
• Dissolve following protocols validated for tablet-based research delivery systems (e.g., solvent screening, dissolution timing, filtered solutions).
• Follow institutional biosafety and chemical-handling requirements.

BPC-157 Lyophilized Powder vs BPC-157 Tablets

The primary differences between the lyophilized powder and oral forms of BPC-157 relate to delivery, stability, and experimental control rather than mechanism. Lyophilized powder is typically favored in laboratory settings because it allows precise reconstitution, flexible concentration ranges, and greater control over experimental variables.

On the other hand, the tablets introduce additional considerations such as excipients, fixed dosing, and altered exposure dynamics, which may influence how the peptide is studied but do not represent a distinct or enhanced mechanism of action.

COA / Quality Assurance

Eternal Peptides makes certificates of analysis available for every product lot, including both the 10 mg lyophilized vials and the 500 mcg tablet products. Each COA typically documents peptide identity (HPLC and/or mass spectrometry), purity analysis, endotoxin levels, sterility testing (where applicable), and specific storage recommendations for that batch.

As a reputable peptide supplier, Eternal Peptides works with Janoshik and other leading testing labs for results you can trust.

You can check that the COA corresponds to the exact lot you ordered, since Eternal Peptides  keeps these records on our Lab Tests page to promote transparency, traceability, and compliance requirements.

Legal / Regulatory Disclaimer

BPC-157 from Eternal Peptides is sold exclusively for research purposes and not for human or veterinary use, clinical administration, or therapeutic applications. The compound is not approved by any regulatory authority, and its safety or effectiveness in humans has not been established.

As the buyer, you are responsible for ensuring compliance with all local laws, institutional biosafety policies, and research-use regulations. Any misrepresentation of intended use may lead to regulatory or legal consequences.

Scientific References

1. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020 Oct 13;10(1):17078.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/ 

2. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel). 2025 Sep 28;18(10):1450.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/ 

3. Cushman CJ, Ibrahim AF, Smith AD, Hernandez EJ, MacKay B, Zumwalt M. Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review. Yale J Biol Med. 2024 Sep 30;97(3):399-413.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

4. Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, Pavlov KH, Petrovic A, Kokot A, Gojkovic S, Krezic I, Drmic D, Rucman R, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020 Mar 15;14(2):153-167.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7096228/ 

5. Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/ 

6. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025 Dec;18(12):611-619.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ 

7. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025 Jul 31:15563316251355551

.https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/